DMI 9523

Drug Profile

DMI 9523

Alternative Names: Ampion; DA-DKP; DM 9523; DMI-9523

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Ampio Pharmaceuticals
  • Class Antirheumatics; Dipeptides; Ketones; Nonsteroidal anti-inflammatories; Piperazines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Immunomodulators; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Phase I Crohn's disease
  • Preclinical Chronic obstructive pulmonary disease
  • Research Eye disorders
  • No development reported Inflammation; Neurological disorders; Rhinitis

Most Recent Events

  • 10 Nov 2016 Efficacy and adverse events data from a phase I trial in Osteoarthritis released by Ampio Pharmaceuticals
  • 01 Nov 2016 Ampio Pharmaceuticals completes a phase I trial for Osteoarthritis (of the hand) in USA (NCT02762760)
  • 08 Sep 2016 Early research in Eye disorders in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top